Secukinumab eases psoriatic arthritis across disease spectrum
Patients saw greatest benefits after 16 weeks on 300mg, according to industry-funded study
Many patients with psoriatic arthritis treated with secukinumab have reduced symptoms and improved quality of life compared with placebo, according to an industry-funded study of more than 2000 patients.
The posthoc analysis used data from patients with psoriatic arthritis participating in four on-label phase three trials.
